Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

This study is testing a next-generation cell therapy called TIL/CAR-TIL therapy — where immune cells (tumor-infiltrating lymphocytes) are taken from a patient's own tumor, engineered to better attack cancer, and infused back into the patient — for people with advanced solid tumors that have not responded to other treatments. **You may be eligible if:** - You have an advanced solid tumor (not a blood cancer) that has not responded to available standard treatments - Your expected survival is more than 3 months - Your heart, lung, liver, and kidney function are adequate - A tissue sample or cancerous fluid from your tumor is available **You may NOT be eligible if:** - You have previously received gene therapy - You have an active serious viral infection such as hepatitis B, hepatitis C, or HIV - You have an active bacterial, viral, or fungal infection - You are pregnant or breastfeeding - You require high-dose steroid treatment Talk to your doctor to see if this trial is right for you.